NCT Number: NCT00240838
An Effectiveness and Safety Study Comparing Acetaminophen (3900 mg/Day) to Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.
The purpose of this study is to compare the effectiveness and safety of acetaminophen extended release caplets and ibuprofen in relieving the muscle soreness that occurs after a marathon.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
About this study
The objective of this randomized, double-blind study is to compare the effectiveness and safety of acetaminophen extended release caplets and ibuprofen in relieving the muscle soreness that occurs in subjects who complete a marathon. Subjects are randomized to receive acetaminophen extended release caplets, 3900 mg/day (two 650 mg caplets taken three times a day, for five days) or ibuprofen caplets, 1200 mg/day (two 200 mg caplets taken three times a day, for five days). The primary measurement of efficacy is the average change in muscle soreness from baseline for both the morning and evening assessments. Safety assessments consist of monitoring adverse events, and a physical examination including vital signs, weight, a review of concomitant medications, and a urine pregnancy test for female subjects. Two hypotheses are examined in a step-down approach. The first hypothesis is that acetaminophen extended release is not inferior to ibuprofen in relieving the muscle soreness that occurs after a marathon. If acetaminophen extended release is not inferior to ibuprofen in relieving the muscle soreness that occurs after a marathon, the second hypothesis is that acetaminophen extended release (3900 mg/day) is superior to ibuprofen (1200 mg/day) in relieving the muscle soreness that occurs after a marathon. Two acetaminophen 650 mg extended release caplets, taken by mouth, three times a day for five days or two ibuprofen 200 mg caplets, taken by mouth, three times a day for five days.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients must complete the marathon
- be able to swallow the study medication
- comply with study requirements regarding the use of any other pain medications before, during or after the marathon
- rate their muscle soreness on the evening after the marathon as at least a 4, on a zero-to-ten point scale
- if female, must not be pregnant or breastfeeding, and must be using an acceptable form of contraception
Exclusion criteria
- Previous diagnosis of osteoarthritis requiring pain medication therapy
- currently have a major medical illness
- have a history of cardiovascular disease, heat injury (heat exhaustion or heat stroke) or collapse during a running or endurance event
- known hypersensitivity to acetaminophen or ibuprofen
Treatment and study plan
Primary outcomes
-
Average change in muscle soreness from baseline for both morning and evening assessments.
Secondary outcomes
-
Average change in muscle soreness from baseline for morning assessments; Average change in muscle soreness from baseline for evening assessments; Average ratings of interference with 1) sleep; 2) morning activity; 3) ability to go for a run
Sponsors and collaborators
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Registry information
Official study title
A Randomized, Double-Blind Study Evaluating Acetaminophen Extended Release Caplets (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.
Important dates
- Study start
- 2003
- Study completion
- 2003
- First posted
- Oct 18, 2005
- Registry last updated
- Jun 29, 2011
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Stellate Ganglion Block to Treat Long COVID 19 Case Series
NCT05812209
Anosmia, Autonomic Nervous System Diseases
Cañon City, Colorado, United States
View Trial DetailsRecovery and Muscle Function After Supplementation With Turmeric
NCT04946981
Muscle Damage, Muscle Soreness
Cork, Ireland
View Trial DetailsStudy of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)
NCT04715932
Abdominal Pain, Anosmia
Montreal, Quebec, Canada
View Trial DetailsHood to Coast Injury Study
NCT00733395
Muscular Diseases, Musculoskeletal Diseases
View Trial Details